svmpharma real world evidence – real world evidence & adaptive pathways

Download SVMPharma Real World Evidence – Real World Evidence & Adaptive Pathways

Post on 14-Apr-2017

63 views

Category:

Healthcare

2 download

Embed Size (px)

TRANSCRIPT

  • Real World Evidence & Adapative Pathways

    SVMPharma Ltd

    CONTACT US enquiry@svmpharma.com

    +44(0) 1252 417030www.svmpharma.com

    http://www.svmpharma.comhttps://twitter.com/svmpharmahttps://twitter.com/svmpharmahttps://www.linkedin.com/company/svmpharma-limitedhttps://www.linkedin.com/company/svmpharma-limitedhttps://plus.google.com/110263897862568461908/postshttps://plus.google.com/110263897862568461908/posts

  • Real World Evidence & Adaptive Pathways

    2 2015 SVMPharma Ltd. All rights reserved.

    Introduction We all want safe and effective medicines to reach

    patients as soon as possible, but as we know, drug

    development, market authorisation and payor

    assessment are all slow sections of a long and

    drawn out journey for a drug.

    But what if patients could have access to

    medicines not just months earlier, but potentially

    8 years earlier?

    Surely this is not practical, or even possible?

    Would this not require a major overhaul of the

    entire process?

    This is exactly what the European Medicines Agency

    (EMA) have in mind, as they lead a broad and diverse

    group of key stakeholders towards a root-and-branch

    upheaval of current practice.

    We are talking about Adaptive Pathways (AP), an

    ambitious and evolving new initiative which

    incorporates Real World Evidence (RWE): clinical data

    collected outside of a conventional randomised

    controlled trial.

    What is Adaptive Pathways and how does

    it work? AP reforms the existing regulatory approach. In fact, it

    goes beyond changes to market authorisation, instead

    taking a lifespan approach that incorporates drug

    development and health technology appraisal.

    Traditionally the product lifecycle of a drug can be

    divided into two distinct phases (pre- and post-

    authorisation). AP replaces this single (go/ no-go)

    market authorisation event with a process of

    reduction of uncertainty alongside iterative periods of

    data collection and regulatory assessment. AP views

    drug development as a continuum with stages of

    regulatory approval and evidence development

    running parallel with marketing. 1, 2

    Could Adaptive Pathways really bring

    forward access to a drug by 8 years? The EMAs primary goal for AP is ensuring timely

    patient access to drugs and they refer to an in-depth

    case study published by the Massachusetts Institute of

    Technology (MIT) NEWDIGS program using a

    hypothetical dyslipidaemia drug. In the traditional

    model this drug would obtain market authorisation 13

    years after phase I studies, whilst in the AP model, the

    drug receives initial authorisation in year 5. This case

    study has been tested with and can be applied to other

    drugs (see figure). 3

    Arent there safety concerns with speeding

    up patient access to drugs? AP is accompanied by an acknowledged level of

    uncertainty and there must be a balance between

    hastening access to new drugs for patients with the

    need for adequate risk-benefit data (an example of

    access versus evidence). The EMA is keen to stress the

    difference between risk and uncertainty which is often

    conflated in public debate. The benefit-risk trade-off

    does not change with AP, only the level of uncertainty.1

  • Real World Evidence & Adaptive Pathways

    3 2015 SVMPharma Ltd. All rights reserved.

    So who has signed up for Adaptive

    Pathways? AP is a collaborative approach with a diverse range of

    participating stakeholders from across Europe and

    beyond. This includes academia, advisory bodies,

    pharmaceutical companies, and regulators. The

    stakeholders are almost universally enthusiastic about

    AP, but some have expressed concerns about how AP

    would be implemented as understandably there can be

    a reluctance to step out of traditional roles.4

    Wait, this sounds familiar, isnt this the

    same as Adaptive Licensing? You may well have heard of Adaptive Licensing since its

    announcement in 2012. In fact, we are talking about

    the same programme, the name was changed to

    Adaptive Pathways last year to reflect the evolution of

    the project through 2-3 years of discussion and

    feedback. The new proposals for AP include some

    notable changes with an increased emphasis on real-

    world data collection. 1, 2

    What role does Real World Evidence play? RWE has been presented as a key component of AP.

    The EMA propose moving away from Randomised

    Controlled Trials (RCTs) being used exclusively as the

    basis for regulatory decisions, instead using the entire

    toolbox of knowledge generation. This includes RWE

    data collection and studies in addition to conventional

    RCTs, pragmatic RCTs and observational trials.

    AP is part of a changing attitude to the perceived lack

    of robustness of RWE and the EMA highlights how

    year-on-year advancements in RWE studies are seeing

    them become more systematic, generate increasingly

    reliable data, and undergo improvements in

    methodology. 1

    What are the benefits? Discussion around AP has delivered a consensus

    amongst the stakeholders on its benefits. This is

    centred around an improved ability to meet patient

    expectations and satisfy unmet medical need by

    expediting the current process. Additionally, AP

    enables innovative, flexible, and patient-centred

    studies to thrive and take centre-stage. RWE data

    collection within AP has the potential to improve our

    understanding of disease processes, epidemiological

    factors, and difficult issues such as adherence, which

    will in turn will allow RCTs to become more efficient. 1

    Another major commercial benefit of AP for

    pharmaceutical companies is that their products will

    have a longer patent lifecycle increasing their revenue

    potential.

    What is happening at the moment? Stage 1 of the pilot project ran from March to

    December 2014 and pharmaceutical companies were

    invited to submit their product for consideration if they

    met three criteria: 1) an iterative development plan

    which could either involve gradual expansion of the

    target population, or a progressive reduction of

    uncertainty based on surrogate endpoints, 2) the

    ability to engage with HTA and other downstream

    stakeholders and 3) monitoring, collection and use of

    real-world data to complement RCTs. Out of 34

    applicants, 10 products were successful in meeting the criteria of iteration, acquisition of real world data, and

    HTA interaction, of which 6 have advanced to the next

    stage which is currently in-progress through to 2016. 5

    But what does it mean for me? The EMA are leading a diverse group of

    stakeholders, who between them cover every

    aspect of the pharmaceutical industry, in planning

    an overhaul of the regulatory process.

    This will impact not only market authorisation but

    the full development and product lifecycle of a

    drug.

    This initiative has given us a clear idea of the

    direction that decision makers wish to take in the

    future. It is apparent that Real World Evidence will

    play an important part in what is to come, but are

    you prepared?

    References & Further Reading 1. Eichler HG, Baird LG, Barker R et al. From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients. Clinical Pharmacology & Therapeutics, 2015. Available at: http://onlinelibrary.wiley.com/doi/10.1002/cpt.59/abstract Accessed Nov 2015. 2. Eichler HG, Oye K, Baird LG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics, 2012. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22336591 Accessed Nov 2015. 3. Baird LG, Teagarden J R, Unger TF et al. New medicines eight years faster to patients: blazing a new trail in drug development with adaptive licensing. SCRIP Regulatory Affairs, 2013. Available at: https://cbi.mit.edu/research-overview/newdigshomepage/newdigs-resources/ Accessed Nov 2015. 4. Baird, L.G. and G. Hirsch. Adaptive licensing: creating a safe haven for discussions. SCRIP Regulatory Affairs, 2013. Available at: https://cbi.mit.edu/research-overview/newdigshomepage/newdigs-resources/ Accessed Nov 2015. 5. EMA. Adaptive pathways to patients: report on the initial experience of the pilot project. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdf Accessed Nov 2015. Cover Image by freepik.com

    http://onlinelibrary.wiley.com/doi/10.1002/cpt.59/abstracthttp://www.ncbi.nlm.nih.gov/pubmed/22336591https://cbi.mit.edu/research-overview/newdigshomepage/newdigs-resources/https://cbi.mit.edu/research-overview/newdigshomepage/newdigs-resources/https://cbi.mit.edu/research-overview/newdigshomepage/newdigs-resources/http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdfhttp://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdf

  • CONTACT SVMPHARMA

    Vaneet NayarDirector SVMPharma

    enquiry@svmpharma.com

    Tel: +44 (0) 1252 417030

    SVMPharma Ltd

    Visit svmpharma.com

    Follow @svmpharma

    Follow on Google+

    Connect via LinkedIn

    Get In Touch

    mailto:enquiry@svmpharma.comhttp://www.svmpharma.com/https://twitter.com/SVMPharmahttps://plus.google.com/u/0/b/11026

Recommended

View more >